Aprea Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Aprea Therapeutics, Inc. filed a Form 8-K dated September 28, 2020, reporting a board appointment. The company is a Delaware corporation headquartered in Boston, Massachusetts, and its common stock trades on Nasdaq under the symbol APRE. The filing does not report quarterly or annual financial results.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other financial metrics.
Material Changes
- On September 28, 2020, the board appointed Michael A. Kelly as a Class III director.
- Mr. Kelly was appointed to the Audit Committee and the Nominating and Corporate Governance Committee.
- He will receive the standard cash compensation for non-employee directors and the equity compensation, including the initial equity grant, described in the company’s April 29, 2020 definitive proxy statement.
Outlook, Risks, and Unusual Items
The filing contains no new guidance, outlook, operating risk disclosures, contingencies, or unusual financial items. A press release discussing the appointment was furnished as Exhibit 99.1; the filing identifies the press release as dated September 29, 2020.
Important Facts to Verify
- Confirm the terms and value of Mr. Kelly’s initial equity grant and ongoing director compensation in the referenced proxy statement.
- Review Exhibit 99.1 for additional background on Mr. Kelly and the appointment.
- Consult the company’s financial filings for current cash, debt, operating results, liquidity, and financing needs, as these matters are not addressed in this Form 8-K.